Ipsen Manufacturing
Ipsen is a biotechnological group aiming to become a leader in specialty healthcare solutions for debilitating diseases. Its strategy is supported by three franchises, neurology, endocrinology and urology-oncology.
Ipsen has a growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumours and a presence in primary care.
The group has more than 4,500 employees spread across R&D and manufacturing sites located in China, France, Ireland, the UK and the US.
Financial Data
-
31st Dec 19 Source: CRO
- €212.4 million turnover
-
€188.9 million
profit - 165 employees
-
31st Dec 18 Source: CRO
- €143.5 million turnover
-
€121.8 million
profit - 141 employees
- 7 more years available »
Ranking
By Turnover
(€212.4 million)- 320th in Top Companies
- 40th in Health
- 37th in Pharma
- 52nd in Manufacturing
By Employees
(165)- 655th in Top Companies
- 80th in Health
- 59th in Pharma
- 97th in Manufacturing
- 165
- €212.4 million
Employees
- James Byrne General Manager
Latest News
- 10:01pm Dublin ranked seventh best city in world to visit by Lonely Planet
- 8:06pm Nama records after-tax profit of €99m for second quarter of year
- 8:06pm Nama records after-tax profit of €99m for second quarter of 2021
- 7:26pm Sunak’s budget signals clear break with previous austerity policies
- 7:18pm Rent the Runway hits $1.7bn valuation after shares open at $23